I
ntravenous infusion of hypertonic saline reduces elevated intracranial pressure (ICP) and increases cerebral perfusion pressure (CPP) in patients suffering from subarachnoid hemorrhage (SAH) (1) (2) (3) (4) . A group in Cambridge, UK, has shown increased cerebral blood flow, middle cerebral artery flow velocity, and brain tissue oxygen (PbO 2 ) in ischemic regions after intravenous infusion of hypertonic saline (5) . The same group also recorded a decrease in lactate-pyruvate ratio at 60 mins after hypertonic saline infusion (6) . How hypertonic saline might affect the intracranial compliance remains to be explored in clinical studies.
The intracranial compliance refers to the pressure-volume relationship which is better described by the pulsatile than the static ICP (7) (8) (9) . The relationship between these different ICP variables and outcome has been investigated in patients with SAH (10). A recently described algorithm for automatic single ICP wave identification and waveform analysis was used (11) . It was found that pulsatility, characterized by the mean ICP wave amplitude, related significantly to both the acute clinical state (Glasgow Coma Score) and the final clinical outcome (Glasgow Outcome Score) (10) . This relationship could not be demonstrated for mean ICP and mean CPP, which were the pressure variables used to guide treatment in these patients. Furthermore, a case report showed how a long-standing bad clinical state of a patient with SAH was rapidly changed by turning management from being guided by static ICP (mean ICP) to being pulsatility (or waveform) guided according to the mean ICP wave amplitude (12) . It was also clearly shown how a reduction in intracranial pulsatility could be achieved by increased drainage of cerebrospinal fluid via an external ventricular drain (12) . Given these promising observations that intracranial pulsatility could be reduced by external drainage of cerebrospinal fluid, and that intracranial pulsatility better correlated with clinical state and outcome, it would be most interesting to explore whether a medical intervention such as osmotherapy, could affect intracranial pulsatility, indicative of the intracranial compliance.
The aim of this study was to describe the effect of a hypertonic saline infusion on intracranial pulsatility (here defined by the mean ICP wave amplitude), and compare it with the effect on static ICP (mean ICP) in patients with SAH. We also explored whether an effect on intracranial pulsatility could be explained by an effect on systemic arterial pulsatility. Except for the results from a pilot study of ours (13) , this has not previously been described.
PATIENTS AND METHODS
This was a retrospective study analyzing prospectively collected data from an intensive care unit in a university hospital. All data were registered as part of studies approved by the Regional Ethics Committee for Medical Research in Southern Norway.
Data Acquisition. ICP was registered via a solid ICP sensor (Codman MicroSensor, Johnson & Johnson, Raynham, MA) coupled to a Codman pressure transducer (Codman ICP Express, Johnson & Johnson). For the continuous arterial blood pressure (ABP) monitoring, an arterial cannula was placed in a radial or femoral artery and connected to a Baxter fluid sensor (Baxter Healthcare, Deerfield, IL). ABP was zeroed at the level of the heart. Both signals were coupled to vital signs Siemens 9000XL Series Monitor (Siemens Medical Systems, Danvers, MA). By means of the Siemens Infinity Gateway Software (Siemens Medical Systems), the continuous ICP and ABP signals were transferred on-line via the hospital network to a computer server and stored as raw data files with sampling rates of 100 Hz. Information on the time and amount of hypertonic saline administered was collected from the patient charts.
ICP/ABP Analysis. The ICP and ABP recordings stored as raw data files on the computer server were analyzed retrospectively using the previously described algorithm implemented in software (11) . This algorithm automatically identifies each cardiac beatinduced single pressure wave and for every consecutive 6-sec time window determines the variables of static pressure (i.e., mean ICP, mean ABP, and mean CPP), and pulsatile pressure (i.e., mean ICP wave amplitude, and mean ABP wave amplitude).
Interventions. From our database of continuous ICP/ABP recordings in patients with SAH, we have retrieved ICP/ABP pressure variables during bolus administration of 7.2% saline in 6% hydroxyethyl starch 200/0.5 (HS). We reported all interventions where we have both the described pressure registrations and precise knowledge of time, and amount of HS given, during a time period from October 2002 to July 2007. Only the first-recorded intervention from an individual patient is used for calculations where nothing else is stated. An intervention was defined as administration of HS wherein the average values of the pressure variables (mean ICP, mean ABP, mean ICP wave amplitude, mean ABP wave amplitude, and mean CPP) were determined for 15-min periods before and after HS infusion (i.e., average of 150 6-sec values both before and after HS). We included interventions where HS was given on the indication of mean ICP Ն15 mm Hg.
Changes in single ICP waves during HS infusion have been illustrated in Figure 1 . Referring to a trend plot of mean ICP during HS infusion (Fig. 1a) , we have shown a 30-sec period of the ICP signal before (Fig. 1b) and after ( Fig. 1c) HS infusion, highlighting two 6-sec time windows wherein the mean ICP wave amplitude was 4.9 and 2.7 mm Hg, respectively (Figs. 1d and e) .
Patients. The study included 20 patients with SAH with acute spontaneous bleeds. Demographics are listed in Table 1 . Except for one patient with a fuciform aneurysm, all patients had their source of bleeding secured (nine clipped, ten coiled). No patients had a decompressive hemicraniectomy or other craniotomy defects at the time of the study. All patients were sedated, intubated, and mechanically ventilated. Care was taken to ensure that external cerebrospinal fluid outflow resistance was kept unaltered, and likewise the ventilator settings were not changed. No other drug boluses like Mannitol, extra sedatives, or vasopressors were given.
Data Analysis. A total of 52 registrations were done in these 20 patients, ranging from one to six per patient. Because of possible bias of repeated measurements, only the first registration in each patient is included in the The results of all interventions (n ϭ 20) were pooled, even though the dose of HS varied between the patients, ranging from 0.8 to 2.0 mL/kg, mean 1.5 (SD 0.4) mL/kg. This was done because the main objective of this study was to compare the effects on static (mean ICP) vs. pulsatile ICP (mean ICP wave amplitude) in the individual patients, not to describe the exact magnitude of the effect. It should be noted that both the variables (mean ICP and mean ICP wave amplitude) were determined simultaneously during the same 6-sec time windows. Hence, comparing these variables was not affected by differences in HS doses between interventions.
The measurement before infusion (baseline) was the mean of the 15-min period before the infusion of HS, and the measurement after infusion was the mean of the 15-min period from the time of maximum effect had been reached for mean ICP and mean ICP wave amplitude.
Statistics. A paired Student's t-test was applied comparing before and after values for each variable, correlation was calculated according to Pearson, and standard linear and multiple regression analyzes were applied (GraphPad InStat, version 3.05, GraphPad Software Inc, San Diego, CA). P-values Յ0.05/ number of comparisons (Bonferroni correction) were considered significant.
RESULTS
HS attenuated both static ICP (mean ICP) and pulsatile ICP (mean ICP wave amplitude) (Tables 1 and 2 ). The changes in mean ABP and mean ABP wave amplitude were not significant ( Table 2) . As a direct consequence of the reduction of mean ICP there was a significant increase in mean CPP (Table 2) . Changes in mean ICP and mean ICP wave amplitude after HS were correlated, whereas baseline values before HS infusion were not (Table  3) . We also analyzed all 52 interventions, and then the p-value was 0.0073 for correlation between baseline mean ICP and baseline mean ICP wave amplitude. For all other calculations there were no differences in statistical significance when all 52 interventions were included in the analysis.
It should be noted that the change in intracranial pulsatility by HS could not be explained by a change in peripheral arterial pulsatility, as there was no correlation between mean ICP wave amplitude and mean ABP wave amplitude, neither for baseline values nor change (Table 3) .
In all the 20 patients, mean ICP was Ն15 mm Hg before infusion. After infusion, mean ICP was Ͻ15 mm Hg in 13 cases. This means that success rate was 65% measured by mean ICP. The results are different when we look at mean ICP wave amplitude, which only fell to a level Ͻ5 mm Hg in 6 of 20 interventions (30%) ( Table 4) . Thus, in 14 of the 20 patients (70%) mean ICP wave amplitude was still Ն5 mm Hg. Table 4 gives the numbers for target achievement also for other target levels than mean ICP Ͻ15 mm Hg and mean ICP wave amplitude Ͻ5 mm Hg, and for CPP. In Figure 2 all the after values for mean ICP, mean ICP wave amplitude, and mean CPP are plotted. Relating to the different target levels suggested by the dotted lines, it is clearly shown how target achievement differed markedly between the different variables.
As further delineated in Figure 3 , the majority of the patients had both elevated mean ICP (Ն15 mm Hg) and mean ICP wave amplitude (Ն5 mm Hg) before HS, whereas only a minority (4 of 20) ended up with mean ICP Ͻ15 mm Hg and mean ICP wave amplitude Ͻ5 mm Hg after HS. The majority ended up with mean ICP Ͻ15 mm Hg but still mean ICP wave amplitude was Ն5 mm Hg (Fig. 3) . As previously mentioned, no intervention other than the HS infusion was performed during the study period. Mean PaCO 2 was 4.5 (SD ϭ 0.4) kPa before and 4.4 (SD ϭ 0.3) kPa after intervention, mean paired difference Ϫ0.05 kPa, p ϭ 0.48. Mean time from the start of the infusion to maximum effect was 32 (range, 5-60) minutes both for mean ICP and mean ICP wave amplitude.
We investigated the correlation of Hunt and Hess score, values of the ICP variables (mean ICP and mean ICP wave amplitude values before, after, and change), dose of HS, and time since admission, to Glasgow Outcome Score at 3 months. Because the number of patients was low, we first did single linear regression for all the different variables and subsequent multiple regression with the two variables displaying the highest r 2 . These were Hunt and Hess score and time since admission. The r 2 for the multiple regression analyses was .40, but of the two variables only Hunt and Hess score made a significant contribution, p ϭ 0.004.
DISCUSSION
Several trials have previously demonstrated how HS-infusion attenuates increased static ICP (mean ICP) after traumatic brain injury and spontaneous SAH (1-4, 14 -17 ). The present study extends previous observations by showing that HS also lowers intracranial pulsatility (mean ICP wave amplitude). This shows that intracranial pulsatility can be changed by a drug intervention. Nevertheless, the effects of HS on static and pulsatile ICP differed, because in the majority of HS infusions the target for pulsatility was not reached despite normalization of static ICP.
The static and pulsatile ICP describes different characteristics of ICP. The static ICP (mean ICP) is influenced not only by pathologic processes inside the skull, but also by the weight of the brain tissue above the point of measurement, and methodologic factors such as baseline pressure level (determined by the zero calibration and drift). The intracranial pulsatility (mean ICP wave amplitude) is the dynamic pressure response evoked by each cardiac beat. Therefore, mean ICP wave amplitude will be accurate even if mean ICP is measured incorrectly because of incorrect zero calibration or drift of the baseline pressure level (18) . As shown in Table 3 , static and pulsatile ICP do correlate, but not very well. We should interpret the p-values with caution. Table 3 shows a significant correlation for change (p Ͻ 0.0001) but not for the baseline values before infusion of HS (p ϭ 0.14). Given a larger number of study subjects, this p-value would most probably be lower, so more robust information can be obtained by looking at the r 2 -values directly. For the correlation between baseline mean ICP and baseline mean ICP wave amplitude, the r 2 is only .11. This means that having measured one of the variables, the value of the other cannot be predicted for any given individual patient. In 1996 Czosnyka et al. (19) published an article looking at short-term correlation between ICP pulse amplitude and mean ICP. For ICP levels Ͻ25 mm Hg, which is the level comparable with our study; they found a correlation coefficient of .405 in patients with good outcome. This gives an r 2 of .16, which is close to our finding, supporting our conclusion that predicting the amplitude from a known mean ICP or vice versa, is impossible. How does this then relate to the findings by Avezaat et al. (7), reporting a strict linear correlation between pulsatile ICP and mean ICP (volume-pressure response vs. ventricular fluid pressure). The linear correlation was demonstrated for six individual dogs. The slope of the correlation curve, however, differed considerably between the dogs. This means that the findings are not contradictive. From our clinical experience, we do also want to add that a linear relationship within a patient can only be true if the patient is not moved or aroused. We therefore do acknowledge the need for further studies to clarify the relationship between mean ICP and pulsatile ICP in the clinical setting.
The dose of HS differed among the 20 HS infusions. This would not be expected to affect the results we were looking for in this study. The focus was not on how much the mean ICP or the mean ICP wave amplitude was actually reduced, but rather on the relationship between the two. Both variables were computed simultaneously during the same 6-sec time windows.
Even though there was a correlation between change in mean ICP and mean ICP wave amplitude, we observed that the target value for mean ICP (Ͻ15 mm Hg) was reached in 65% whereas the target for mean ICP wave amplitude (Ͻ5 mm Hg) was reached in only 30% of interventions (Table 4 ). This differential effect of HS on static and pulsatile ICP is further illustrated in Figure 2 . Certainly, the cutoff levels for mean ICP and mean ICP wave amplitude used here can be discussed. We chose 15 mm Hg for mean ICP. This is regarded as the upper limit of normal ICP. Most clinicians would agree that ICP is increased Ն15 mm Hg, even though the threshold for using osmotherapy in clinical practice would mostly be 20 or even 25 mm Hg. We have chosen to show results for different levels of cutoff, both for mean ICP and mean CPP, but especially for mean ICP wave amplitude (Fig. 2) . A lot more data are needed to establish a cutoff that is proven to distinguish between outcome groups for this variable. For the time being, we use the cutoff level of 5 mm Hg in an ongoing study (ClinicalTrials.gov Identifier: NCT00248690) based on findings from three previous studies correlating mean ICP wave amplitude levels to outcome. 1) Mean ICP wave amplitude levels were highly predictable for which patients with idiopathic normal pressure hydrocephalus that responded to shunt treatment (20) . 2) In patients with severe SAH, mean ICP wave amplitude, and to a lesser extent mean ICP, was highly related to the acute clinical state (i.e., Glasgow Coma Score) and the final clinical outcome (Glasgow Outcome Score) (10). 3) In a cohort of ICP recordings of head injury patients with high mean ICP, mean ICP wave amplitude was elevated in those with bad outcome (21) .
Based on the findings that there might be a correlation between mean ICP wave amplitude Ͼ5 mm Hg and worsened outcome (10, 20, 21) , the great discrepancy between target achievements for the different variables in our study is important. In the majority of interventions, the mean ICP wave amplitude was still too high even though both mean ICP and mean CPP were within acceptable limits. This could mean that our approach to optimizing intracranial compliance is not aggressive enough when treatment is based on mean ICP and mean CPP measurements.
The intracranial compliance as related to the pressure-volume curve has previously been studied (7, (22) (23) (24) (25) ; the previous studies indicated that intracranial compliance is better described by the pulsatile than the static ICP because the pulse pressure is the pressure response to the change in intracranial volume caused by each heartbeat (7, 26) . In animals the pulse amplitude correlated with the intracranial compliance (8) , and in patients with intracranial bleeds, the mean ICP wave amplitude correlated with intracranial compliance determined by the Spiegelberg compliance monitor (27) . Therefore, it is reasonable to argue that the reduction of mean ICP wave amplitude shown here reflects an improvement in intracranial compliance.
The changes in intracranial pulsatility could also be caused by changes in vascular pulsatility; this option seems less likely because we found no correlation between mean ICP and ABP wave amplitudes (Table 3) . Hence, the intracranial pulse pressure amplitude was not merely mediated by systemic arterial systolic and diastolic pressure differences. These observations concur with those of Eide et al. (21) in head injury patients, namely of no association between intracranial and systemic arterial blood pulse pressure amplitudes, even during different states of cerebral autoregulation.
The relevance of our findings and of measuring pulsatile ICP altogether could be questioned by the fact that we demonstrated no correlation between outcome and ICP measurements in this study. The only variable correlating to outcome being the Hunt and Hess score. We will argue that we cannot expect to find a significant correlation between ICP measurements during a short time period (i.e., 15-mins duration before and after HS) and final outcome. The design of this study does not allow for such conclusions. But because there are emerging evidence of a correlation between pulsatile ICP and outcome in other studies (10, 20, 21) , we find documenting an effect of osmotherapy important. The issue of correlation to outcome is of course the most important issue, and we are addressing this in an ongoing study (ClinicalTrials.gov Identifier: NCT00248690).
